Concord Biotech (BOM:543960) ROCE % : 24.96% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Concord Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Concord Biotech's annualized ROCE % for the quarter that ended in Dec. 2024 was 24.96%.

Concord Biotech ROCE % Historical Data

The historical data trend for Concord Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Concord Biotech ROCE % Chart

Concord Biotech Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

25.97

32.95

21.75

26.34

28.82

Concord Biotech Quarterly Data
	Mar20	Mar21	Mar22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial								29.95	33.15	20.47	32.15	24.96

Concord Biotech ROCE % Calculation

Concord Biotech's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	4151.169	/	( ( (15139.818 - 1918.443)	+	(17007.085 - 1421.554) )	/ 2 )
	=	4151.169	/	( (13221.375	+	15585.531)	/ 2 )
	=	4151.169	/	14403.453
	=	28.82 %

Concord Biotech's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	4049.988	/	( ( (17643.448 - 1417.126)	+	(0 - 0) )	/ 1 )
	=	4049.988	/	( ( 16226.322	+	0 )	/ 1 )
	=	4049.988	/	16226.322
	=	24.96 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Concord Biotech (BOM:543960) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Concord Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Concord Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Concord Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Concord Biotech Ltd (BOM:543960) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CONCORDBIO:India

Address

Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015

Website

https://www.concordbiotech.com

Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.

Concord Biotech Headlines

No Headlines